Novavax Stock Soars on FDA Approval for COVID Vaccine

Biotech stock Novavax Inc (NASDAQ:NVAX) is skyrocketing today, up 26% at $8.48 at last glance, after the U.S. Food & Drug Administration (FDA) approved the company's COVID-19 vaccine. The shot, Nuvaxovid, differs from the others in that it is protein-based, not mRNA-based, and is designed for those between the ages of 12 and 64 who have underlying conditions that put them at greater risk due to the illness. Should these gains hold, NVAX will mark its highest single-day percentage gain since last May. Jumpin ...